Predicting breast cancer patient outcome: Researchers identify new genes

Not a day goes by without a new story about the environment. Although we often consider the environment on a global scale, cells in our body also have to contend with environmental factors. New studies from a team of researchers from the Research Institute of the MUHC and McGill University show that the environment surrounding breast cancer cells plays a crucial role in determining whether tumor cells grow and migrate or whether they fade away. Their study is the first to identify the genes behind this environmental control and correlate them with patient outcome. Their findings are published in this week’s issue of Nature Medicine.

“A tumour can not exist on its own. It has to be supported and nourished by the cell types around it, the microenvironment,” says senior author Dr Morag Park, Director of the molecular oncology group at the Research institute if the MUHC. “When we began this study there was little known about the importance of this microenvironment on cancer initiation and progression. We now know that this environment is pivotal; different patients have distinct tumour microenvironments at a gene level. Our findings show that the gene profile of these distinct microenvironments can be used to determine clinical outcome – who will fare well and who will not.”

Dr Park, a professor of oncology, biochemistry, and medicine at McGill University, and her team analyzed tissue from 53 breast cancer patients. They used a unique technique, laser capture microdissection (LCM), to separate tumour cells from microenvironment tissue. They compared the gene expression between the microenvironment tissue and controls using micro-array analysis. From thousands of genes they identified 163, which correlated with patient outcome. A good outcome was defined as having no tumour metastasis and tumour migration and non-responsiveness to therapy was considered poor outcome.

From the original 163 genes, the team further identified a panel of 26 specific genes that could be used to accurately predict clinical outcome. This 26 gene-profile, called the stromal derived prognostic predictor (SDPP), was used to predict outcome from a second set of beast cancer patients.

“We were able to show that the SDPP effectively predicts outcome in a second group of patients,” says Dr Park, “This panel accurately forecasted patient status, suggesting that this may be a promising diagnostic tool.

“Our next steps are to develop this 26-gene predictor into a functional test. We are currently working on this and we anticipate a product for clinical trials within a year,” adds Park.

“This work takes tremendous dedication and collaboration from a number of people including pathologists, surgeons, oncologists as well as researchers. I would like to thank the outstanding work done by G. Finak from the laboratory of Dr M. Hallett of McGill’s Computer Science Department, the breast surgeons of the MUHC, including Dr S. Meterissian, and by the Department of Pathology at McGill, where Dr A. Omeroglu works."

Source: McGill University

Related stories:

Unlocking mysteries of brain cancer, stroke
New studies at the University of Adelaide, Australia, will delve into some of the crucial issues surrounding death by brain tumours and stroke.
'Bionic' nerve to bring damanged limbs and organs back to life
University of Manchester researchers have transformed fat tissue stem cells into nerve cells — and now plan to develop an artificial nerve that will bring damaged limbs and organs back to life.
Molecular profiling can accurately predict survival in colon cancer patients
Researchers in The Netherlands have developed a method of accurately predicting which patients with colon cancer are most likely to have their disease recur after surgery and who would, therefore, be likely to benefit from additional chemotherapy.
Cancer cells in blood can identify risk of recurrence in breast cancer
Cancer cells circulating in the blood, or circulating tumour cells (CTCs), are known to be associated with a bad prognosis in women with metastatic breast cancer. Now, for the first time, a group of scientists have shown that they can also detect CTCs before and after chemotherapy treatment and hence may be able to identify those patients likely to have a recurrence of their cancer after such treatment in future.
Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery. The authors say their finding is particularly important because the focus of recent pathological studies of response to neoadjuvant therapies has been on the primary tumour rather than nodal sites.
A black and white look at breast cancer mortality
African and African American women are more likely to die of breast cancer than their white counterparts because they tend to get the disease before the menopause, suggests new research from the University of East Anglia and the Children’s Hospital Boston in collaboration with researchers in the US and Italy.
Checking more lymph nodes linked to cancer patient survival
Why do patients with gastric or pancreatic cancer live longer when they are treated at cancer centers or high-volume hospitals than patients treated at low-volume or community hospitals?
Has cancer spread? Research identifies best way to find answers so treatment can begin
For patients with head and neck cancer, accurately determining how advanced the cancer is and detecting secondary cancers usually means undergoing numerous tests – until now. New Saint Louis University research has found that the PET-CT scanner can be used as a stand-alone tool to detect secondary cancers, which occur in 5 to 10 percent of head and neck cancer patients.

News discussion:

Medicine & Health news